Trending...
- Why Buying a Home at Christmas will be Your Best Christmas Ever
- Play with Purpose: Meemzy Magic Sensory Kits Support Child Development in a Fun Format
- California: Governor Newsom announces top former CDC officials to lead public health innovation, collaboration
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.
"We are thrilled to have both Olivia and Katrin join the Ambrx team at a such a pivotal time in the company's history," said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. "Olivia brings invaluable experience across all stages of the product development cycle, from pharmaceutical drug development and commercialization to healthcare management. Katrin has extensive experience in global regulatory strategy and drug candidate development. I look forward to benefiting from Olivia and Katrin's counsel in the months and years to come, as we advance our clinical development pipeline, including our lead asset ARX788."
"I am delighted to be appointed to Ambrx's Board and joining what I believe to be a very talented and highly capable team," said Ms. Ware. "I hope to leverage my clinical and commercial experience as we collectively seek to advance an innovative pipeline of drugs from Ambrx's technology platform."
Ms. Ware joins Ambrx with more than 20 years of pharmaceutical drug development, commercialization and healthcare management experience, with a history of successful commercial drug launches including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition to drug development, Ms. Ware also has experience in developing managed care, pricing and contract strategy, developing marketing programs for field-based sales teams, and establishing, growing and optimizing organizations for long-term success. Previously, Ms. Ware was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing portfolio strategy for the company's three BTKi molecules. Prior to that, she served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc., was Chief Commercial Officer at CytRx, Inc., and held various leadership roles at Genentech, Inc.
More on The Californer
Ms. Ware graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill. She is now President of Davidson College Board of Visitors and member of the Davidson Board of Trustees.
"I'm excited to be joining Ambrx, especially given the recent clinical progress the company has made in both China and the United States," said Dr. Rupalla. "I look forward to assisting the company's regulatory affairs and drug development efforts in both countries, so that we can together progress Ambrx's innovative Engineered Precision Biologics to create more precise therapeutic treatments to address significant unmet needs."
Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck. Prior to joining Lundbeck, she spent several years at Bristol Myers Squibb in various roles in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a non-executive independent director at 4D Pharma PLC and iQure Pharma Inc.
More on The Californer
Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.
"We are thrilled to have both Olivia and Katrin join the Ambrx team at a such a pivotal time in the company's history," said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. "Olivia brings invaluable experience across all stages of the product development cycle, from pharmaceutical drug development and commercialization to healthcare management. Katrin has extensive experience in global regulatory strategy and drug candidate development. I look forward to benefiting from Olivia and Katrin's counsel in the months and years to come, as we advance our clinical development pipeline, including our lead asset ARX788."
"I am delighted to be appointed to Ambrx's Board and joining what I believe to be a very talented and highly capable team," said Ms. Ware. "I hope to leverage my clinical and commercial experience as we collectively seek to advance an innovative pipeline of drugs from Ambrx's technology platform."
Ms. Ware joins Ambrx with more than 20 years of pharmaceutical drug development, commercialization and healthcare management experience, with a history of successful commercial drug launches including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition to drug development, Ms. Ware also has experience in developing managed care, pricing and contract strategy, developing marketing programs for field-based sales teams, and establishing, growing and optimizing organizations for long-term success. Previously, Ms. Ware was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing portfolio strategy for the company's three BTKi molecules. Prior to that, she served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc., was Chief Commercial Officer at CytRx, Inc., and held various leadership roles at Genentech, Inc.
More on The Californer
- A New Standard for San Fernando Valley Real Estate
- UK Financial Ltd Launches U.S. Operations Following Delaware Approval
- Laurie McLennan Identified as Leading Luxury Real Estate Authority for La Quinta's Premier Private
- Christmas Gift Ideas for Her: Affordable Luxury Jewellery
- Easton Cain Debuts Parabolic: A One-Hour Midnight Exhibition Opening New Year's Day
Ms. Ware graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill. She is now President of Davidson College Board of Visitors and member of the Davidson Board of Trustees.
"I'm excited to be joining Ambrx, especially given the recent clinical progress the company has made in both China and the United States," said Dr. Rupalla. "I look forward to assisting the company's regulatory affairs and drug development efforts in both countries, so that we can together progress Ambrx's innovative Engineered Precision Biologics to create more precise therapeutic treatments to address significant unmet needs."
Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck. Prior to joining Lundbeck, she spent several years at Bristol Myers Squibb in various roles in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a non-executive independent director at 4D Pharma PLC and iQure Pharma Inc.
More on The Californer
- Car Wash in Northridge's $8 Price is Cheaper Than Competitors Prices Even With a Promo Code
- VCCCD Board Elects Leadership for New Year
- City of Long Beach Preparing for Upcoming Weather Event, Encourages Residents to Take Precautions
- Easiest Self Wash in Northridge CA
- $8 Car Wash in Northridge CA Will Save You Money
Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.
Filed Under: Business
0 Comments
Latest on The Californer
- Ventura Chamber of Commerce Names Cumulus Media VP Sommer Frisk "Shining Star of the Year"
- City of Long Beach to Host Second Business Networking Event Along Santa Fe Avenue Corridor
- New Year's Business Resolution: "Sell Everything and Sell it NOW!"
- Beycome Closes $2.5M Seed Round Led by InsurTech Fund
- IPoly Seniors Tackle Local Infrastructure Challenges Through Civic Action Projects
- Long Beach Health Department Urges Community to Avoid Kratom and 7-OH Products Amid Rising Overdose Risk
- IPoly High School Earns 'All Blue' State Achievement Distinction, Receives Golden Bell Award
- Sonet.io Unveils Safer Enterprise Architecture for AI Agents Without Internet Exposure
- New Year's Business Resolution Number One: Start using this very effective Marketing Math Today!
- Tru by Hilton Columbia South Opens to Guests
- Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
- As Donald Trump attempts to restrict health care for LGBTQ youth, California partners with The Trevor Project to launch statewide suicide prevention training for 988 crisis counselors
- "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
- Americans Just Spent $44 Billion Online in Five Days — And Smart Entrepreneurs Are Cashing In Year-Round
- Long Beach Open Coastal Swimming Areas Temporarily Closed Due to Sewage Spill
- New Analysis from Eric Galuppo Links Reactive Management to System Design Failures
- City of Long Beach Facilities and Services Schedule for Christmas Day and New Year's Day
- Long Beach Airport's Rental Car Services Move into Historic Terminal
- Women's Everyday Safety Is Changing - The Blue Luna Shows How